NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
View Top Employees from NeoGenomics LaboratoriesWebsite | http://neogenomics.com |
Ticker | NEO |
Revenue | $408 million |
Employees | 1,460 (1,375 on RocketReach) |
Founded | 2002 |
Address | 9490 NeoGenomics Way, Fort Myers, Florida 33912, US |
Phone | (239) 768-0600 |
Fax | (239) 690-4237 |
Technologies |
JavaScript,
HTML,
Google Analytics
+100 more
(view full list)
|
Industry | Hospitals and Health Care, Medical Testing & Clinical Laboratories, Biotechnology, Cytogenetics, Healthcare, Science and Engineering, Flow Cytometry, Health Care, Fluorescence In Situ Hybridization (FISH), Medical, Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, Next-Gen Sequencing (NGS) |
Web Rank | 214101 |
Web Visits | 226590 |
Keywords | Flow Cytometry |
Competitors | Bio Reference Laboratories Inc, Clinical Pathology Laboratories, Dynacare, Invitae, Natera |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 62 Companies, NAICS Code 621 Companies, NAICS Code 541712 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 6215 Companies, NAICS Code 54 Companies, NAICS Code 62151 Companies, NAICS Code 54171 Companies |
Looking for a particular NeoGenomics Laboratories employee's phone or email?
The NeoGenomics Laboratories annual revenue was $408 million in 2024.
Chris Smith is the CEO of NeoGenomics Laboratories.
1,375 people are employed at NeoGenomics Laboratories.
NeoGenomics Laboratories is based in Fort Myers, Florida.
The NAICS codes for NeoGenomics Laboratories are [62, 621, 541712, 541, 5417, 6215, 54, 62151, 54171].
The SIC codes for NeoGenomics Laboratories are [873, 87].